Laser Force Cytology for In-Process Monitoring of High-Titer Orf Virus Vectors: Process Integration with Optimized Nuclease Treatment and Clarification in Pharmaceutical Manufacturing
Vaccines · 14.11.2026 · 14 (11) · 981
DOI: 10.3390/vaccines14110981 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 14.11.2026. Verfasst von Linus G. Weber und 9 weiteren Autor:innen. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Applied Sciences Mittelhessen, Giessen, Germany.
Abstract (Originalsprache)
Background/Objectives: Orf virus (ORFV) is a versatile viral vector platform with applications in vaccine development and oncolytic therapy. Its large poxviral genome allows for the insertion and expression of multiple heterologous transgenes, making ORFV particularly attractive for the development of recombinant vaccines and therapeutic vectors. Efficient manufacturing of ORFV-based products requires high infectious virus yields while maintaining robust downstream processing and product recovery. In this study, we used a high-titer ORFV harvest to investigate nuclease treatment and clarification as key early downstream processing steps.
Methods
Host cells were monitored during the infection phase using Laser Force Cytology to support the identification of an optimal harvest time. In addition, crude harvest pretreatment was optimized using enhanced NaCl concentrations and endonuclease treatment before clarification filtration.
Results
Amplification of ORFV viral vectors in HEK293F derivatives resulted in peak infectious titers of up to 3.3 × 109 IU mL−1. The addition of NaCl allowed for efficient degradation of DNA impurities by Denarase® High Salt while stabilizing the ORFV vector. Optimal enzyme performance was observed using 550 mM NaCl and 90 U mL−1 Denarase® High Salt for 7 h at 21 °C, resulting in 92% depletion of residual double-stranded DNA (dsDNA). For clarification filtration, a combination of polypropylene-based depth filters with retention rates of 5 and 0.5 µm recovered 91% of ORFV while depleting 33% dsDNA and 36% protein.
Conclusions
This comprehensive data define optimized harvest timing, nuclease treatment and the clarification strategy of high-titer ORFV material, paving the way for pharmaceutical manufacturing of ORFV vectors.
Förderung
- University of Applied Sciences Mittelhessen, Giessen, Germany
Zitieren
APA
Weber, L. G., Talavera, P. L. L., Rothenburg, J., Roth, B., Evans, Z. L., Hebert, C. G., Hasse, C., Pagallies, F., Amann, R., & Wolff, M. W. (2026). Laser Force Cytology for In-Process Monitoring of High-Titer Orf Virus Vectors: Process Integration with Optimized Nuclease Treatment and Clarification in Pharmaceutical Manufacturing. Vaccines, 14(11), 981. https://doi.org/10.3390/vaccines14110981
Vancouver
Weber LG, Talavera PLL, Rothenburg J, Roth B, Evans ZL, Hebert CG, et al. Laser Force Cytology for In-Process Monitoring of High-Titer Orf Virus Vectors: Process Integration with Optimized Nuclease Treatment and Clarification in Pharmaceutical Manufacturing. Vaccines. 2026;14(11):981. doi:10.3390/vaccines14110981
BibTeX
@article{Weber2026,
author = {Weber, Linus G. and Talavera, Paul L. L. and Rothenburg, Jannik and Roth, Bernhard and Evans, Zachary L. and Hebert, Colin G. and Hasse, Christof and Pagallies, Felix and Amann, Ralf and Wolff, Michael W.},
title = {Laser Force Cytology for In-Process Monitoring of High-Titer Orf Virus Vectors: Process Integration with Optimized Nuclease Treatment and Clarification in Pharmaceutical Manufacturing},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {981},
doi = {10.3390/vaccines14110981}
}
EUVIMED